



6100 Merriweather Dr., Suite 600
Columbia, MD 21044
410-884-2900

CONTINUING REVIEW APPROVAL

CR00399467

DATE: 12 Oct 2022

TO: Devin Keating

PROTOCOL: American Heart Association-TX - 1.0, Pragmatic Randomized Clinical Trial of Early Dronedarone versus Usual Care to Change and Improve Outcomes in Persons with First-Detected Atrial Fibrillation (CHANGE AFib). (Pro00057635)

CONTINUING REVIEW APPROVAL DATE: 11 Oct 2022

EXPIRATION DATE: 11 Oct 2023

Thank you for providing the information required for the Advarra IRB to conduct continuing review of the protocol.

In addition to the information you provided, the IRB reviewed the current protocol referenced above, the Consent Template(s) for the study, and other supporting information.

The IRB approved continuation of the above referenced protocol. The IRB determined there were no changes required to the current Consent Template(s).

Please Note: This approval notice is for the IRB approval of the protocol only. The Principal Investigator for each site must complete a separate Continuing Review submission to receive an IRB Approval notice allowing them to continue to conduct the study.

If the study is expected to last beyond the approval period, you must request and receive re-approval prior to the expiration date noted above. A report to the Board on the status of this study is due prior to the expiration date or at the time the study closes, whichever is earlier. It is recommended that you submit status reports at least 4 weeks prior to your expiration date to avoid any additional fees or lapses in approval.

Approved investigators and sites are required to submit to Advarra for review, and await a response prior to implementing, any amendments or changes in the protocol; advertisements or recruitment materials ("study-related materials"); investigators; or sites (primary and additional).

Approved investigators and sites are required to notify Advarra of the following reportable events, including, but not limited to: unanticipated problems involving risks to subjects or others; unanticipated adverse device effects; protocol violations that may affect the subjects' rights, safety, or well-being and/or the completeness, accuracy and reliability of the study data; subject death; suspension of enrollment; or termination of the study.



Please review the IRB Handbook located in the “Reference Materials” section of the Advarra CIRBI™ Platform (www.cirbi.net). A copy of the most recent IRB roster is also available.

Thank you for continuing to use Advarra IRB to provide oversight for your research project.